Prelude Therapeutics (PRLD) Liabilities and Shareholders Equity (2019 - 2026)

Prelude Therapeutics has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $119.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 15.3% year-over-year to $119.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $470.6 million (down 36.25% YoY) and the FY2025 annual result came in at $141.3 million, down 19.49% from the prior year.
• Liabilities and Shareholders Equity eased to $119.6 million in Q1 2026 per PRLD's latest filing, from $141.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $280.7 million in Q1 2022 and troughed at $94.8 million in Q3 2025.
• A 5-year average of $204.3 million and a median of $220.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity grew 25.93% in 2023, then sank 51.95% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $220.5 million in 2022, then climbed by 25.93% to $277.7 million in 2023, then slumped by 36.79% to $175.5 million in 2024, then fell by 19.49% to $141.3 million in 2025, then retreated by 15.34% to $119.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $119.6 million, $141.3 million, and $94.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.